- France
- /
- Electronic Equipment and Components
- /
- ENXTPA:LBIRD
Why Investors Shouldn't Be Surprised By Lumibird SA's (EPA:LBIRD) P/E
Lumibird SA's (EPA:LBIRD) price-to-earnings (or "P/E") ratio of 22.6x might make it look like a strong sell right now compared to the market in France, where around half of the companies have P/E ratios below 15x and even P/E's below 8x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
Lumibird hasn't been tracking well recently as its declining earnings compare poorly to other companies, which have seen some growth on average. It might be that many expect the dour earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be extremely nervous about the viability of the share price.
See our latest analysis for Lumibird
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Lumibird.How Is Lumibird's Growth Trending?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Lumibird's to be considered reasonable.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 6.8%. Even so, admirably EPS has lifted 83% in aggregate from three years ago, notwithstanding the last 12 months. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been more than adequate for the company.
Turning to the outlook, the next three years should generate growth of 33% per annum as estimated by the dual analysts watching the company. That's shaping up to be materially higher than the 11% per year growth forecast for the broader market.
With this information, we can see why Lumibird is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
The Key Takeaway
While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
As we suspected, our examination of Lumibird's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.
A lot of potential risks can sit within a company's balance sheet. You can assess many of the main risks through our free balance sheet analysis for Lumibird with six simple checks.
Of course, you might also be able to find a better stock than Lumibird. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:LBIRD
Lumibird
Designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide.
Reasonable growth potential with adequate balance sheet.